Show simple item record

AuthorShibeeb, sapha
AuthorAhmad, Muneera Naseer
Available date2021-09-15T07:37:47Z
Publication Date2021-08-31
Publication NameJournal of Blood Medicine
Identifierhttp://dx.doi.org/10.2147/JBM.S316014
CitationShibeeb S, Ahmad MN. Thrombotic and Hypercoagulability Complications of COVID-19: An Update. J Blood Med. 2021;12:785-793 https://doi.org/10.2147/JBM.S316014
URIhttp://hdl.handle.net/10576/23122
AbstractThe current COVID-19 pandemic emerged in December 2019, in China, affecting millions of people worldwide. COVID-19 is mainly a disease of the respiratory system, yet systematic complications have also been reported among SARS-CoV-2 infected patients. Thrombotic complications are one of the severe clinical outcomes of COVID-19, especially among critically ill patients, and are associated with poor prognosis. To date, many studies have concluded that COVID-19 increases the incidence of thrombotic events and coagulopathies; however, the exact mechanism behind such a disease outcome is not well known. Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines. As a result, most critically diseased COVID-19 patients are managed with prophylactic anticoagulant, yet some still develop thrombotic episodes. Therefore, better understanding of the mechanisms behind the thrombotic complications is needed to develop treatments that specifically target such pathways, which may aid in better disease management and improve the prognosis.
Languageen
PublisherDovepress
SubjectCOVID-19
Thrombosis
Hypercoagubility
TitleThrombotic and Hypercoagulability Complications of COVID-19: An Update
TypeArticle
Pagination785-793
Volume Number12
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record